Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.2
Journals
JPM
Special Issues
Inflammation and Immunity in Cardiovascular Diseases
share announcement

Inflammation and Immunity in Cardiovascular Diseases

A special issue of Journal of Personalized Medicine (ISSN 2075-4426). This special issue belongs to the section "Mechanisms of Diseases".

Deadline for manuscript submissions: 15 February 2027 | Viewed by 710

Special Issue Editor

Dr. Nathan A. Holland

E-Mail Website
Guest Editor
Department of Medical Education, Paul L. Foster School of Medicine, Texas Tech Health Sciences Center El Paso, 130 Rick Francis Dr., El Paso, TX 79905, USA
Interests: inflammation; ischemia–reperfusion injury; cardiovascular physiology; hypertension; cardiovascular disease

Special Issue Information

Dear Colleagues,

Chronic inflammation and dysregulated immune responses are central contributors to the development and progression of cardiovascular diseases (CVDs), including atherosclerosis, heart failure, and ischemic injury. As our understanding of the immune–cardiovascular interface deepens, precision strategies targeting inflammatory pathways have emerged as promising tools for both risk stratification and therapeutic intervention. This Special Issue invites original research and review articles that explore the roles of innate and adaptive immunity, inflammatory signaling cascades, and immune–metabolic crosstalk in cardiovascular pathology. We welcome studies examining the impact of comorbidities such as obesity, diabetes, and environmental exposures on immune activation in the cardiovascular system. Submissions highlighting novel biomarkers, therapeutic targets, or personalized treatment strategies in the context of cardiovascular inflammation are especially encouraged. Our aim is to bring together interdisciplinary insights that advance the precision medicine approach to cardiovascular care.

Dr. Nathan A. Holland
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Personalized Medicine is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • cardiovascular inflammation
  • immune modulation
  • ischemia–reperfusion injury
  • personalized medicine
  • inflammatory biomarkers
  • cardiometabolic disease
  • environmental exposures

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Review

16 pages, 1052 KB  
Review
Personalized Sudden Cardiac Death Risk Stratification in Hypertrophic Cardiomyopathy: Beyond Conventional Risk Scores
by Jacopo Costantino, Federico Ballatore, Daniele Porcelli, Barbara Romani, Massimiliano Campoli, Lorenzo Maria Zuccaro, Giulia Marchionni, Maria Alfarano, Samuel Costantino and Cristina Chimenti
J. Pers. Med. 2026, 16(6), 287; https://doi.org/10.3390/jpm16060287 - 26 May 2026
Viewed by 352
Abstract
Hypertrophic Cardiomyopathy (HCM) is one of the most common inherited cardiomyopathies and remains an important cause of ventricular arrhythmias and sudden cardiac death (SCD), particularly in younger individuals. Although the annual incidence of arrhythmic death is relatively low in contemporary cohorts, identifying those [...] Read more.
Hypertrophic Cardiomyopathy (HCM) is one of the most common inherited cardiomyopathies and remains an important cause of ventricular arrhythmias and sudden cardiac death (SCD), particularly in younger individuals. Although the annual incidence of arrhythmic death is relatively low in contemporary cohorts, identifying those patients who may benefit from primary prevention with an implantable cardioverter-defibrillator (ICD) remains a major clinical challenge. Current risk stratification strategies rely on two principal paradigms. The European approach is centered on the HCM Risk-SCD score, whereas the American approach is mainly based on major clinical risk markers. Both strategies have important strengths and limitations, reflecting the persistent difficulty of accurately predicting arrhythmic events in such a heterogeneous disease. The HCM Risk-SCD score has demonstrated robust external validation and high specificity for identifying patients at higher risk, but it may fail to recognize some vulnerable individuals who remain below conventional treatment thresholds. For this reason, several additional risk modifiers have gained increasing relevance in contemporary practice. Among them, extensive late gadolinium enhancement, left ventricular systolic dysfunction, apical aneurysm, and clinically meaningful genetic findings may provide important incremental prognostic information beyond traditional models. Emerging disease-modifying therapies, in particular Mavacamten, may also influence future risk assessment. However, whether these improvements translate into a true reduction in SCD risk remains uncertain. Importantly, the decision to implant an ICD should not depend on numerical risk alone. It should arise from a process of shared decision-making integrating estimated risk, treatment burden, competing comorbidities, age, lifestyle, and patient values. In this context, the concept of an individualized threshold of “acceptable risk” becomes central. In conclusion, prevention of SCD in HCM is moving beyond conventional scores toward a personalized and dynamic framework in which predictive tools, advanced phenotyping, evolving therapies, clinical expertise, and patient preferences are combined to guide individualized care. Full article
(This article belongs to the Special Issue Inflammation and Immunity in Cardiovascular Diseases)
►▼ Show Figures

Graphical abstract

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop